Edition:
United States

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

166.50CHF
11:31am EST
Change (% chg)

CHF0.00 (+0.00%)
Prev Close
CHF166.50
Open
CHF166.90
Day's High
CHF167.60
Day's Low
CHF166.20
Volume
10,177
Avg. Vol
13,230
52-wk High
CHF188.10
52-wk Low
CHF137.30

COPN.S

Chart for COPN.S

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for COPN.S.

Overall

Beta: --
Market Cap(Mil.): €2,239.17
Shares Outstanding(Mil.): 14.42
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 29.57 30.46
EPS (TTM): 0.24 -- --
ROI: 5.61 15.39 14.82
ROE: 6.12 16.58 16.24

BRIEF-Cosmo announces details of successful phase III clinical trials of LuMeBlue

* Announces details of successful phase III clinical trials of LuMeBlue which will be presented at its research and development day

Nov 29 2016

Cosmo shares jump on colonoscopy trial results

ZURICH Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent on Thursday after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.

Nov 10 2016

CORRECTED-Cosmo shares jump on colonoscopy trial results

ZURICH, Nov 10 Shares in Swiss-listed drugmaker Cosmo Pharmaceuticals jumped more than 10 percent on Thursday after it reported its dye tablets helped doctors detect intestinal growths during colonoscopies.

Nov 10 2016

BRIEF-Cosmo Pharmaceuticals: successful outcome of phase III clinical trial for LuMeBlue

* Announces successful outcome of phase III clinical trial for LuMeBlue

Nov 10 2016

BRIEF-Cosmo Pharmaceuticals H1 profits after tax decline to EUR 5.6 mln

* H1 revenues increased by 58.3 percent to 31.6 million euros ($35.02 million)

Jul 29 2016

Earnings vs. Estimates

No consensus analysis data available.